Advances in Vaccines, Checkpoint Blockade, and Chimeric Antigen Receptor-Based Cancer Immunotherapeutics

被引：0

作者：

Agarwal, Disha ^{[1
]}

Sharma, Gaurav ^{[1
]}

Khadwal, Alka ^{[2
]}

Toor, Devinder ^{[3
]}

Malhotra, Pankaj ^{[2
]}

机构：

[1] Postgrad Inst Med Educ & Res, Dept Translat & Regenerat Med, 5th Floor Res Block B Sect 12, Chandigarh 160012, India

[2] Postgrad Inst Med Educ & Res, Dept Clin Hematol & Med Oncol, Chandigarh, India

[3] Amity Univ Uttar Pradesh, Amity Inst Virol & Immunol, Noida, India

来源：

CRITICAL REVIEWS IN IMMUNOLOGY | 2024年 / 45卷 / 01期

关键词：

vaccines; cancer; immunotherapy; CTLA-4; PD-1; CAR-T cells; CAR-NK cells; immune surveillance; immune exhaustion; MESSENGER-RNA VACCINES; NATURAL-KILLER-CELLS; T-CELLS; DENDRITIC CELLS; NK-92; CELLS; CD28; GENERATION; RESISTANCE; THERAPY; PD-1;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Increase in cancer cases and research driven by understanding its causes, facilitated development of novel targeted immunotherapeutic strategies to overcome nonspecific cytotoxicity associated with conventional chemotherapy and radiotherapy. These target specific immunotherapeutic regimens have been evaluated for their efficacy, including: (1) vaccines harnessing tumor specific/associated antigens, (2) checkpoint blockade therapy using monoclonal antibodies against PD1, CTLA-4 and others, and (3) adoptive cell transfer approaches viz. chimeric antigen receptor (CAR)-cellbased therapies. Here, we review recent advancements on these target specific translational immunotherapeutic strategies against cancer/s and concerned limitations.

引用

页码：65 / 80

页数：16

共 50 条

[41] Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell
Lin, Chu
Zhang, Jun
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1869 (02): : 200 - 215
[42] From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
Voynova, Elisaveta
Kovalovsky, Damian
CELLS, 2021, 10 (11)
[43] Non-Conventional Allogeneic Anti-BCMA Chimeric Antigen Receptor-Based Immune Cell Therapies for Multiple Myeloma Treatment
Du, Zhicheng
Zhu, Sumin
Zhang, Xi
Gong, Zhiyuan
Wang, Shu
CANCERS, 2023, 15 (03)
[44] Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies
Tanaka, Junji
HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 11 - 19
[45] Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma
Yu, Tianshu
Wang, Xianhuo
Bai, Ou
Zhang, Huilai
Qian, Wenbin
CANCER BIOLOGY & MEDICINE, 2025,
[46] Advances in Chimeric Antigen Receptor Immunotherapy for Chronic Lymphocytic Leukemia
Riches, John C.
Gribben, John G.
DISCOVERY MEDICINE, 2013, 16 (90) : 295 - 302
[47] Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade
Li, Hongzhi
Yuan, Weihua
Bin, Shufang
Wu, Guang
Li, Panyuan
Liu, Min
Yang, Jifeng
Li, Xiang
Yang, Kaiyan
Gu, Haihua
AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (02): : 688 - 703
[48] In Situ Bioconjugation of Synthetic Peptides onto Universal Chimeric Antigen Receptor T Cells for Targeted Cancer Immunotherapies
Cardle, Ian I.
Scherer, Dylan R.
Jensen, Michael C.
Pun, Suzie H.
Sellers, Drew L.
ACS NANO, 2025, 19 (05) : 5750 - 5768
[49] Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice
Berzero, Giulia
Picca, Alberto
Psimaras, Dimitri
CURRENT OPINION IN ONCOLOGY, 2020, 32 (06) : 603 - 612
[50] Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)
Poojary, Rayansh
Song, Andy Fang
Song, Benny Shone
Song, Carly Shaw
Wang, Liqing
Song, Jianxun
MOLECULAR AND CLINICAL ONCOLOGY, 2023, 19 (06)

← 1 2 3 4 5 →